Factors Influencing Growth Inhibition of Mycoplasma Pneumoniae by Immune Sera
Overview
General Medicine
Physiology
Authors
Affiliations
Protective Effect of Vaccines in Experimental Mycoplasma pneumoniae Disease.
Fernald G, CLYDE W Infect Immun. 1970; 1(6):559-65.
PMID: 16557776 PMC: 415942. DOI: 10.1128/iai.1.6.559-565.1970.
An experimental model for human mycoplasma disease.
CLYDE Jr W Yale J Biol Med. 1968; 40(5-6):436-43.
PMID: 5673852 PMC: 2591633.
Characteristics of virulent, attenuated, and avirulent Mycoplasma pneumoniae strains.
Lipman R, CLYDE Jr W, Denny F J Bacteriol. 1969; 100(2):1037-43.
PMID: 5359607 PMC: 250191. DOI: 10.1128/jb.100.2.1037-1043.1969.
Bradbury J, Jordan F J Hyg (Lond). 1971; 69(1):73-82.
PMID: 5291753 PMC: 2130842. DOI: 10.1017/s0022172400021264.
Modifications of the growth inhibition test and its application to human T-mycoplasmas.
Black F Appl Microbiol. 1973; 25(4):528-33.
PMID: 4572983 PMC: 380855. DOI: 10.1128/am.25.4.528-533.1973.